A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
Status:
Completed
Trial end date:
2018-09-14
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, open-label, multicentre study of AZD6094 in combination with gefitinib in
patients with epidermal growth factor receptor (EGFR) mutation positive (m+) and progressed
on EGFR Tyrosine kinase inhibitor (TKI) treatment.